Improving Western Blot Reproducibility: Antibodies to Automation

Using directed integration of antibody genes by CRISPR/Cas9 and TALENs, the construction of large libraries in mammalian cells containing a single antibody gene/cell has been achieved. This accomplishment has enabled the construction of libraries containing millions of monoclonal, stable, cell lines displaying IgG-formatted antibodies on their surface, and from which novel, high-affinity binders can be isolated. This technology also allows for the selection of antibodies with improved biophysical properties from libraries of variants.

The webinar will focus on the relationship between analytics of biotherapeutic products and the interpretation of data to build and support a solid regulatory Chemistry, Manufacturing and Control (CMC) strategy. The importance of data interpretation is illustrated in the development of biosimilars and new biological entities, as well as in regulatory specifications regarding biotherapeutic products.

Peptide and oligonucleotide drugs are versatile therapeutics with a growing range of applications and many similarities in terms and of manufacturing and regulation.

The science of medicine has allowed us to make incredible advances in diagnosing and treating diseases. But the complexity of human biology is staggering. Every person is unique and in many ways, so are diseases. Yet the digital revolution in healthcare provides new ways to both collect high-quality data from each patient and connect it to data from large pools of other patients for analysis. This enables us to arrive at a deeper understanding of how to treat an individual. Only then can we see what distinguishes each of us as individuals, and translate that into personalized and thus improved care for every person. Real-world evidence, molecular information generated from next-generation sequencing, data from wearable devices and mobile apps and novel clinical trials are transforming the future of care.